Free Trial

Diaceutics (DXRX) Competitors

Diaceutics logo
GBX 116.50 0.00 (0.00%)
As of 07/4/2025

DXRX vs. AGL, YGEN, ABDX, PRM, GDR, GENI, VRCI, DMTR, LLAI, and LLA

Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), GENinCode (GENI), Verici Dx (VRCI), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.

Diaceutics vs. Its Competitors

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Diaceutics has a net margin of -10.90% compared to ANGLE's net margin of -890.91%. Diaceutics' return on equity of -7.15% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Diaceutics-10.90% -7.15% -6.06%
ANGLE -890.91%-76.01%-29.89%

Diaceutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

52.4% of Diaceutics shares are held by institutional investors. Comparatively, 18.8% of ANGLE shares are held by institutional investors. 34.3% of Diaceutics shares are held by company insiders. Comparatively, 16.2% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diaceutics£26.08M3.77-£2.84M-£3.37-34.55
ANGLE£2.44M8.25-£21.76M-£6.76-0.92

Diaceutics currently has a consensus price target of GBX 160, indicating a potential upside of 37.34%. ANGLE has a consensus price target of GBX 40, indicating a potential upside of 540.00%. Given ANGLE's higher probable upside, analysts plainly believe ANGLE is more favorable than Diaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Diaceutics' average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.

Company Overall Sentiment
Diaceutics Neutral
ANGLE Neutral

Summary

Diaceutics beats ANGLE on 10 of the 13 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXRX vs. The Competition

MetricDiaceuticsDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£98.32M£810.32M£5.55B£2.96B
Dividend YieldN/A5.44%5.22%5.02%
P/E Ratio-34.552.1527.66147.88
Price / Sales3.77498.43419.21258,917.23
Price / Cash3.1211.4236.8927.97
Price / Book2.542.858.034.61
Net Income-£2.84M£334.07B£3.18B£5.90B
7 Day Performance-2.49%0.15%2.93%1.04%
1 Month Performance-10.38%-3.16%1.72%4.36%
1 Year Performance-10.04%-7.55%34.39%82.36%

Diaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXRX
Diaceutics
N/AGBX 116.50
flat
GBX 160
+37.3%
-10.0%£98.32M£26.08M-34.55151High Trading Volume
AGL
ANGLE
1.8156 of 5 stars
GBX 6.50
-3.7%
GBX 40
+515.4%
-57.6%£20.95M£2.44M-0.96650Gap Down
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 6.89
-1.6%
N/A-31.6%£13.34M£3.84M-16.7584News Coverage
Gap Down
PRM
Proteome Sciences
N/AGBX 3.21
+5.7%
N/A-18.9%£9.48M£10.88B-2.32240Gap Down
GDR
genedrive
N/AGBX 1.41
+0.4%
N/A-18.6%£7.98M£1.50M-0.3943
GENI
GENinCode
N/AGBX 2.34
+4.0%
N/A-67.3%£4.15M£2.67M-0.682,300Gap Down
VRCI
Verici Dx
N/AGBX 1.25
+11.1%
N/A-82.0%£3.79M£5.91M-0.7219Gap Up
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down
LLAI
LungLife AI
N/AGBX 3.50
-17.6%
N/A-75.9%£1.16M£33.87K-0.2815Gap Down
High Trading Volume
LLA
LLA.L,0P0001T9GN,0
N/AN/AN/AN/A£0.00N/A-25.0015Gap Down
High Trading Volume

Related Companies and Tools


This page (LON:DXRX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners